Search Results - A. N. Babenko
- Showing 1 - 3 results of 3
-
1
A Retrospective Analysis of the Clinical Studies of a Drug "Flakozid" in the Treatment of Diseases of the Hepatobiliary System by V. V. Bortnikova, V. V. Karabaeva, L. V. Krepkova, P. G. Mizina, A. N. Babenko, N. S. Mikheeva, O. N. Karabaeva
Published 2021-08-01Introduction. The medicine "Flakozid" with hepatoprotective effect has been developed at the VILAR. The drug is presented in dosage form-tablets of 0.1 g for oral drug administrationAim. To analyze the clinical efficacy and safety of "Flakozid" therapy according to clinical labor...
Get full text
Article -
2
Identification of luteolin-7-glucoside metabolites after oral administration and development of a method for their quantitative analysis by G. V. Adamov, O. L. Saybel, A. N. Babenko, E. S. Melnikov, A. I. Radimich, O. Yu. Kulyak, L. V. Krepkova
Published 2024-09-01Introduction. The development and registration of antiviral drugs is an urgent task. Flavonoids, in particular, luteolin-7-glycoside (cinaroside, luteolin-7-O-glycoside) demonstrate high broad-spectrum antiviral activity in vitro, and the industrial regulations for the production of luteolin-7-glyco...
Get full text
Article -
3
Retrospective Analysis of Experimental and Clinical Studies of Flakozid in Viral Hepatitis by V. V. Karabaeva, L. V. Krepkova, A. N. Babenko, V. V. Bortnikova, T. V. Fateeva, P. G. Mizina, N. S. Mikheeva, O. N. Karabaeva
Published 2021-11-01Introduction. Viral hepatitis (HV) by its socio-economic significance occupies one of the leading places in human infectious pathology, therefore, the development of fundamentally new methods of prevention, diagnosis and treatment, as well as the creation of new antiviral drugs remain relevant. An a...
Get full text
Article